Drug Trial Radar · NCT06208150
A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide
Last checked: Nov 19, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
838
Actual
Start
Jan 22, 2024
Primary completion
Apr 1, 2026
Study completion Mar 31, 2028
Sponsor
- Lead sponsor
- Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
- Sponsor type
- Industry
- First posted
- Jan 17, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to compare the effectiveness of either talquetamab plus pomalidomide (Tal-P) or talquetamab plus teclistamab (Tal-Tec) with elotuzumab, pomalidomide, and dexamethasone (EPd) or pomalidomide, bortezomib, and dexamethasone (PVd).
Conditions
- Multiple Myeloma
Interventions
TalquetamabDrug
Talquetamab will be administered as a SC injection.
PomalidomideDrug
Pomalidomide will be administered orally.
TeclistamabDrug
Teclistamab will be administered as a SC injection.
ElotuzumabDrug
Elotuzumab will be administered intravenously.
DexamethasoneDrug
Dexamethasone will be administered either orally or intravenously.
BortezomibDrug
Bortezomib will be administered as a SC injection.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression Free Survival (PFS)Time frame: Up to 3 years 5 months
Locations
242 sites in 27 countries. Site status is shown where the registry gives one.
UCSF Fresno
Clovis, California
UCLA
Santa Monica, California
Yale University School Of Medicine
New Haven, Connecticut
Medical Oncology Hematology Consultants, PA
Newark, Delaware
Memorial Healthcare System
Hollywood, Florida
Moffitt Cancer Center
Tampa, Florida
Winship Cancer Institute Emory University
Atlanta, Georgia
City of Hope Cancer Center
Newnan, Georgia
Kootenai Health
Coeur d'Alene, Idaho
Loyola University Medical Center
Maywood, Illinois
University of Iowa Health Care
Waukee, Iowa
Norton Cancer Institute
Louisville, Kentucky
Our Lady of the Lake Hospital
Baton Rouge, Louisiana
Luminis Health Center for Cancer and Blood Disorders
Annapolis, Maryland
University of Maryland School of Medicine
Baltimore, Maryland
The Sidney Kimmel Comprehensive Cancer Center at John Hopkins
Baltimore, Maryland
University of Michigan
Ann Arbor, Michigan
Henry Ford Cancer Institute
Detroit, Michigan
Henry Ford Health Providence Southfield Hospital
Southfield, Michigan
University Of Minnesota
Minneapolis, Minnesota
Mayo Clinic Rochester
Rochester, Minnesota
Regions Hospital
Saint Paul, Minnesota
University of Nebraska
Omaha, Nebraska
Dartmouth Hitchcock Medical Center
Lebanon, New Hampshire
John Theurer Cancer Center at Hackensack University Medical Center
Hackensack, New Jersey
Roswell Park Cancer Institute
Buffalo, New York
Weill Cornell Medical College
New York, New York
SUNY Upstate Medical University
Syracuse, New York
Duke University Medical Center
Durham, North Carolina
Gabrail Cancer Center
Canton, Ohio
Louis Stokes Cleveland VA Med Ctr
Cleveland, Ohio
Cleveland Clinic
Cleveland, Ohio
Oregon Health And Science University
Portland, Oregon
Penn State Milton S Hershey Medical Ctr
Hershey, Pennsylvania
Thomas Jefferson University
Philadelphia, Pennsylvania
West Penn Hospital
Pittsburgh, Pennsylvania
University Of Pittsburgh Medical Center UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania
Medical University of South Carolina
Charleston, South Carolina
Bon Secours Saint Francis Cancer Center
Greenville, South Carolina
UT Southwestern Parkland Hospital
Dallas, Texas
Showing 40 of 242 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.